Correlation Between Lipocine and Conduit Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Lipocine and Conduit Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lipocine and Conduit Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lipocine and Conduit Pharmaceuticals, you can compare the effects of market volatilities on Lipocine and Conduit Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lipocine with a short position of Conduit Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lipocine and Conduit Pharmaceuticals.

Diversification Opportunities for Lipocine and Conduit Pharmaceuticals

0.37

Correlation Coefficient

Lipocine  Conduit Pharmaceuticals

Weak diversification

The 3 months correlation between Lipocine and Conduit is 0.37. Overlapping area represents the amount of risk that can be diversified away by holding Lipocine and Conduit Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Conduit Pharmaceuticals and Lipocine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lipocine are associated (or correlated) with Conduit Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Conduit Pharmaceuticals has no effect on the direction of Lipocine i.e., Lipocine and Conduit Pharmaceuticals go up and down completely randomly.

Pair Corralation between Lipocine and Conduit Pharmaceuticals

Given the investment horizon of 90 days Lipocine is expected to generate 2.41 times less return on investment than Conduit Pharmaceuticals. But when comparing it to its historical volatility, Lipocine is 3.51 times less risky than Conduit Pharmaceuticals. It trades about 0.04 of its potential returns per unit of risk. Conduit Pharmaceuticals is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  9.03  in Conduit Pharmaceuticals on October 10, 2024 and sell it today you would lose (0.83) from holding Conduit Pharmaceuticals or give up 9.19% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Lipocine  vs.  Conduit Pharmaceuticals

Lipocine

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lipocine are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Lipocine may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Conduit Pharmaceuticals

Risk-Adjusted Performance

1 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Conduit Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental indicators, Conduit Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Lipocine and Conduit Pharmaceuticals

The main advantage of trading using opposite Lipocine and Conduit Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lipocine position performs unexpectedly, Conduit Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Conduit Pharmaceuticals will offset losses from the drop in Conduit Pharmaceuticals' long position.

The idea behind Lipocine and Conduit Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.